EP Patent

EP0656789B1 — Method for treating a lfa-1-mediated disorder

Assigned to Genentech Inc · Expires 1997-12-17 · 28y expired

What this patent protects

A method is provided for administering to a mammal suffering from, or at risk for, multiple sclerosis, an initial dosing of a therapeutically effective amount of an anti-LFA-1 antibody, followed by a subsequent intermittent dosing of a therapeutically effective amount of the anti…

USPTO Abstract

A method is provided for administering to a mammal suffering from, or at risk for, multiple sclerosis, an initial dosing of a therapeutically effective amount of an anti-LFA-1 antibody, followed by a subsequent intermittent dosing of a therapeutically effective amount of the anti-LFA-1 antibody wherein the antibody is administered to the mammal no more than once per week in the intermittent dosing.

Drugs covered by this patent

Patent Metadata

Patent number
EP0656789B1
Jurisdiction
EP
Classification
—
Expires
1997-12-17
Drug substance claim
No
Drug product claim
No
Assignee
Genentech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.